05:40:33 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies utvecklar produkter som separerar och renar molekyler vid framställning av nya läkemedel. Teknologin baseras på kromatografi som har som avsikt att förbättra läkemedelssubstansen och tillföra kroppen renare läkemedel. Kunderna återfinns främst inom den europeiska marknaden där produkterna säljs via olika distributionspartners och vidare till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.

Kalender

2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2020-11-10 08:00:00

Bio-Works Technologies (Nasdaq First North) recently signed a distribution agreement with BioLinx India Pvt Ltd, Mumbai, to import, distribute, promote and sell all its products in India to Academia, Hospitals & Clinics and Biotech SMEs. Bio-Works has also engaged Dr Ravi Rayanade as Director Regional Sales. Dr Rayanade is a seasoned bioprocess expert with a wide network in the Indian biotech industry.

Bio-Works is further strengthening its presence in the Indian market to take advantage of the many opportunities arising from local companies' expertise in developing new vaccines and biopharmaceuticals. These new vaccines and therapies are based on proteins, peptides or oligonucleotides. Many Indian biotech companies have more than 20 years' experience in bioprocessing and continue to develop their strength as a low-cost manufacturing base for the global markets.

The Indian biopharma industry is growing at 12 percent yearly. According to the 15th Bio-Spectrum Biopharma Survey result for the year 2018-19, the biopharma industry revenues surpassed USD 3bn. The previous year's revenue was USD 2.4bn. India has more than 40 innovative Biopharma companies ranging from start-ups to well-established players. The Indian chromatography market is estimated to be worth USD 65mn and the pre-packed chromatography columns market is anticipated to exhibit lucrative growth owing to the increased R&D efforts of the biopharmaceutical and academic sectors. An important market driver is the rapid increase in the demand for biopharmaceutical products such as vaccines and monoclonal antibodies.

Bio-Works' proprietary agarose resins, WorkBeads™, have a wide variety of functionalities: WorkBeads affimAb for protein A-based affinity, WorkBeads 40Q, WorkBeads 40S and WorkBeads 40 TREN for ion-exchange, WorkBeads 40/100/1000/10000 SEC for size exclusion and WorkBeads 40 IDA, WorkBeads 40 NTA and WorkBeads 40 NiMAC for immobilised metal ion affinity chromatography. They are all specifically developed with commercial scale manufacturing in mind. WorkBeads, with stronger and more rigid agarose beads, offer faster mass transport, higher yields and higher purity offering opportunities for process intensification, which may result in a lower CoGS than competitors. 

"Bio-Works' is encouraged by the high level of competence in downstream processing in India, which we have encountered when meeting potential customers through Dr Rayanade's network. In many cases, the knowledge and level of expertise is on a par with the US and European biopharma companies, which facilitates our technical sales process and which is also reflected in the positive test results we have seen from many local customers. We see a solid foundation in India with great opportunities to increase sales and expectations going forward", says Mr Jonathan Royce, Bio-Works' CEO.

"The addition of Bio-Works' products has significantly strengthened our portfolio and our offering to the BioPharma and Drug Discovery segments. Over the last decade we have been steadily adding more and more products to our portfolio, catering to segments such as the Stem Cell Industry, Molecular Diagnostics, Drug Discovery and Biopharma, so Bio-Works is a very welcome addition. It also gives us an opportunity to be a part of Biopharma's innovative research and manufacturing in the future." says Mr. Girish Nair Founder and Managing Director of BioLinx India Pvt Ltd.